MicroPort CardioFlow Medtech Corporation
微创心通医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2160)

VOLUNTARY ANNOUNCEMENT FIRST TWO CLINICAL APPLICATIONS OF OUR THIRD-GENERATION TAVI PRODUCT

This announcement is made by MicroPort CardioFlow Medtech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the third-generation transcatheter aortic heart valve implantation product independently developed by the Group ("**Third-Generation TAVI Product**") which is equipped with an upgraded retrievable steerable delivery system was successfully applied by the the heart teams of Fuwai Hospital of the Chinese Academy of Medical Sciences (中國醫學科學院阜外醫院) and Shanxi Provincial Hospital of Cardiovascular Diseases (山西省心血管病醫院) to treat two patients with severe aortic stenosis. The patients are now recovering well with significant relief of related symptoms. The successful first-in-man applications of our Third-Generation TAVI Product marked its entry into the clinical application phase and further enriched our TAVI product offering to increase our competitiveness.

Originated from the Group's deep understanding of clinical needs and pain points, our self-developed Third-Generation TAVI Product is an iteration of VitaFlow Liberty®, our second-generation TAVI product which is now widely used in TAVI procedures. The delivery system of this product is upgraded with a highly innovative steerable function, which is designed to help cross the aortic arch and the native valve, facilitate the delivery process to achieve less tissue damage, enhance valve coaxiality during pre-positioning and release, make it easier to anchor in the appropriate position, further reduce the maneuver difficulty and increase positioning accuracy, thus improving the procedure success rate and enhancing the therapeutic effects. The unique spatial curvature is more in line with the human heart structure and is suitable for a variety of challenging anatomies. Meanwhile, the limit switch on the handle of the delivery system helps physicians to reduce the rate of intraoperative mishandling and further optimizes the procedure process.

The first two successful clinical applications of the Third-Generation TAVI Product is another important milestone of the Group's comprehensive deployment in the field of structural heart disease, and a manifestation of our solid technical reserves and innovative research & development capabilities in the field of structural heart diseases. The product impresses physicians with its excellent ease-of-use, more accurate positioning and improved procedure efficiency. We look forward to the launch of the Third-Generation TAVI Product as soon as possible to treat more patients with aortic valve disease.

There is no assurance that the Company will ultimately be able to successfully commercialize the Third-Generation TAVI Product. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC, October 16, 2023

As at the date of this announcement, the executive Directors are Mr. Jeffrey R Lindstrom, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Mr. Chen Guoming, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.